Photobiomodulation therapy combined with static magnetic field is better than placebo in patients with fibromyalgia: a randomized placebo-controlled trial.

Autor:	Ribeiro NF; Post-Graduate Program in Rehabilitation Sciences, Laboratory of Phototherapy and Innovative Technologies in Health (LaPIT), Nove de Julho University, São Paulo, Brazil., Leal-Junior ECP; Post-Graduate Program in Rehabilitation Sciences, Laboratory of Phototherapy and Innovative Technologies in Health (LaPIT), Nove de Julho University, São Paulo, Brazil - ernesto.leal.junior@gmail.com.; Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.; ELJ Consultancy, São Paulo, Brazil., Johnson DS; Multi-Radiance Medical, Solon, OH, USA., Demchak T; Indiana State University, Terre Haute, IN, USA., Machado CM; Post-Graduate Program in Rehabilitation Sciences, Laboratory of Phototherapy and Innovative Technologies in Health (LaPIT), Nove de Julho University, São Paulo, Brazil., Dias LB; Post-Graduate Program in Rehabilitation Sciences, Laboratory of Phototherapy and Innovative Technologies in Health (LaPIT), Nove de Julho University, São Paulo, Brazil., DE Oliveira MF; Post-Graduate Program in Rehabilitation Sciences, Laboratory of Phototherapy and Innovative Technologies in Health (LaPIT), Nove de Julho University, São Paulo, Brazil., Lino MM; Post-Graduate Program in Rehabilitation Sciences, Laboratory of Phototherapy and Innovative Technologies in Health (LaPIT), Nove de Julho University, São Paulo, Brazil., Rodrigues WD; Post-Graduate Program in Rehabilitation Sciences, Laboratory of Phototherapy and Innovative Technologies in Health (LaPIT), Nove de Julho University, São Paulo, Brazil., Santo J; Post-Graduate Program in Rehabilitation Sciences, Laboratory of Phototherapy and Innovative Technologies in Health (LaPIT), Nove de Julho University, São Paulo, Brazil., DE Barros CN; Post-Graduate Program in Rehabilitation Sciences, Laboratory of Phototherapy and Innovative Technologies in Health (LaPIT), Nove de Julho University, São Paulo, Brazil., Casalechi HL; Post-Graduate Program in Rehabilitation Sciences, Laboratory of Phototherapy and Innovative Technologies in Health (LaPIT), Nove de Julho University, São Paulo, Brazil., Tomazoni SS; Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
Jazyk:	angličtina
Zdroj:	European journal of physical and rehabilitation medicine [Eur J Phys Rehabil Med] 2023 Dec; Vol. 59 (6), pp. 754-762. Date of Electronic Publication: 2023 Oct 17.
DOI:	10.23736/S1973-9087.23.07928-5
Abstrakt:	Background: Fibromyalgia is a syndrome characterized by generalized chronic pain and tenderness in specific areas. Photobiomodulation therapy (PBMT) using low-level laser therapy and/or light emitting diode therapy is an electrophysical agent that can be used alone or together with a static magnetic field (PBMT-sMF) to promote analgesia in several health conditions. Little evidence exists regarding the effects of using PBMT and PBMT-sMF in patients with fibromyalgia; this evidence is conflicting. Aim: We aimed to investigate the effects of using PBMT-sMF versus a placebo on reduction of the degree-of-pain rating, impact of fibromyalgia, pain intensity, and satisfaction with treatment in patients with fibromyalgia. Design: A prospectively registered, monocentric, randomized placebo-controlled trial, with blinding of patients, therapists, and assessors, was performed. Setting: The study was conducted at the Laboratory of Phototherapy and Innovative Technologies in Health (LaPIT) in Brazil, between March and October 2020. Population: Ninety female patients with fibromyalgia were randomized to undergo either PBMT-sMF (N.=45) or placebo (N.=45) treatment. Methods: Patients from both groups received nine treatment sessions, three times a week, for 3 weeks. Clinical outcomes were collected at baseline, the end of treatment, and at the follow-up appointment 4 weeks post-treatment. The primary outcome was the degree-of-pain rating, measured by the reduction of the tender point count. Results: A decrease in the degree-of-pain rating was observed in patients allocated to the PBMT-sMF group, decreasing the number of tender points when compared to placebo group at the end of treatment (P<0.0001) and at the follow-up assessment (P<0.0001). Patients did not report any adverse events. Conclusions: PBMT-sMF is superior to placebo, supporting its use in patients with fibromyalgia. Clinical Rehabilitation Impact: PBMT-sMF might be considered an important adjuvant to the treatment regimens of patients with fibromyalgia.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu